Gracell Biotechnologies (GRCL) News Today → Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (From Paradigm Press) (Ad) Free GRCL Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsEarningsHeadlinesOwnershipShort InterestSocial MediaStock AnalysisAnalyst ForecastsEarningsHeadlinesOwnershipShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative March 3, 2024 | finance.yahoo.comGRCL Mar 2024 10.000 call(CONTRFebruary 24, 2024 | marketbeat.com49,158 Shares in Gracell Biotechnologies Inc. (NASDAQ:GRCL) Purchased by Pathstone Family Office LLCPathstone Family Office LLC acquired a new position in shares of Gracell Biotechnologies Inc. (NASDAQ:GRCL - Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 49,158 shares of the company's stock, valued atFebruary 22, 2024 | finance.yahoo.comGracell Biotechnologies Acquisition CompletedFebruary 22, 2024 | marketbeat.comGracell Biotechnologies (NASDAQ:GRCL) Given Hold Rating at Stifel NicolausStifel Nicolaus reaffirmed a "hold" rating and set a $10.25 price objective (down from $11.00) on shares of Gracell Biotechnologies in a research report on Thursday.February 22, 2024 | globenewswire.comGracell Biotechnologies Acquisition CompletedFebruary 22, 2024 | marketbeat.comTrading was temporarily halted for "GRCL" at 07:02 PM with a stated reason of "News pending."February 22, 2024 | marketbeat.comBarclays PLC Increases Stake in Gracell Biotechnologies Inc. (NASDAQ:GRCL)Barclays PLC grew its stake in Gracell Biotechnologies Inc. (NASDAQ:GRCL - Free Report) by 2,862.1% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 311,520 shares of the company's stock after acquiring anFebruary 21, 2024 | seekingalpha.comAstraZeneca Deal For Gracell Biotechnologies Closing Tomorrow (Includes CVR)February 21, 2024 | investing.comGracell Biotechnologies Inc. (GRCL)February 20, 2024 | marketbeat.comStock Traders Buy High Volume of Gracell Biotechnologies Put Options (NASDAQ:GRCL)Gracell Biotechnologies Inc. (NASDAQ:GRCL - Get Free Report) was the recipient of unusually large options trading on Tuesday. Stock investors bought 13,143 put options on the company. This represents an increase of approximately 481% compared to the average volume of 2,262 put options.February 20, 2024 | finanznachrichten.deGracell Biotechnologies Inc.: Gracell Biotechnologies Announces Shareholders' Approval of Merger AgreementFebruary 20, 2024 | finance.yahoo.comGracell Biotechnologies Announces Shareholders’ Approval of Merger AgreementFebruary 20, 2024 | globenewswire.comGracell Biotechnologies Announces Shareholders' Approval of Merger AgreementFebruary 17, 2024 | finance.yahoo.comGRCL Mar 2024 2.500 callFebruary 17, 2024 | seekingalpha.comGRCL Gracell Biotechnologies Inc.February 10, 2024 | marketbeat.comGracell Biotechnologies Inc. (NASDAQ:GRCL) Given Consensus Rating of "Moderate Buy" by BrokeragesGracell Biotechnologies Inc. (NASDAQ:GRCL - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the eight ratings firms that are currently covering the stock, Marketbeat reports. Four investment analysts have rated the stock with a hold rating and four have given a buy rFebruary 9, 2024 | marketbeat.comGracell Biotechnologies (NASDAQ:GRCL) Sets New 12-Month High at $10.36Gracell Biotechnologies (NASDAQ:GRCL) Sets New 52-Week High at $10.36February 6, 2024 | marketbeat.comGracell Biotechnologies Inc. (NASDAQ:GRCL) is Vivo Capital LLC's 9th Largest PositionVivo Capital LLC grew its holdings in Gracell Biotechnologies Inc. (NASDAQ:GRCL - Free Report) by 174.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 10,881,144 shares of the company's stock aftJanuary 29, 2024 | finance.yahoo.comGracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T GC012F as Early-Line Treatment of Multiple MyelomaJanuary 11, 2024 | marketbeat.comAstraZeneca: Rebound in 2024 with double-digit earnings growth (GRCL)AstraZeneca's stock rose 8.95% in the past month on a bullish outlook, driven by growing sales of cancer and diabetes drugs and a strategic acquisitionJanuary 3, 2024 | finance.yahoo.comGracell Biotechnologies Inc. Sponsored ADR (GRCL) is a Great Momentum Stock: Should You Buy?December 31, 2023 | businesswire.comGRACELL BIOTECHNOLOGIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of ...December 30, 2023 | marketbeat.comBarclays PLC Trims Stock Position in Gracell Biotechnologies Inc. (NASDAQ:GRCL)Barclays PLC cut its holdings in shares of Gracell Biotechnologies Inc. (NASDAQ:GRCL - Free Report) by 94.8% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 10,517 shares of the company's stock after selling 191,808 shDecember 29, 2023 | marketbeat.comGracell Biotechnologies Inc. to Post FY2026 Earnings of ($0.82) Per Share, HC Wainwright Forecasts (NASDAQ:GRCL)Gracell Biotechnologies Inc. (NASDAQ:GRCL - Free Report) - Investment analysts at HC Wainwright decreased their FY2026 earnings estimates for shares of Gracell Biotechnologies in a research note issued to investors on Tuesday, December 26th. HC Wainwright analyst E. Bodnar now anticipates that thDecember 27, 2023 | marketbeat.comGracell Biotechnologies (NASDAQ:GRCL) Earns "Equal Weight" Rating from Wells Fargo & CompanyWells Fargo & Company reissued an "equal weight" rating and set a $10.00 price objective on shares of Gracell Biotechnologies in a report on Wednesday.December 27, 2023 | markets.businessinsider.comMaintaining Hold on Gracell Biotechnologies Amidst AstraZeneca Acquisition ProspectsDecember 26, 2023 | msn.comWhy China-Based Gracell Biotechnologies (GRCL) Stock Is Soaring TodayDecember 26, 2023 | finance.yahoo.comGracell Biotechnologies to be acquired by AstraZeneca, furthering cell therapy ambition across oncology and autoimmune diseasesDecember 26, 2023 | marketbeat.comGracell Biotechnologies (NASDAQ:GRCL) Stock Rating Reaffirmed by BTIG ResearchBTIG Research reaffirmed a "neutral" rating on shares of Gracell Biotechnologies in a report on Tuesday.December 26, 2023 | markets.businessinsider.comGracell Biotechnologies, Stratasys, Hollysys Automation Technologies And Other Big Stocks Moving Higher In Tuesday's Pre-Market SessionDecember 26, 2023 | tmcnet.comGRCL Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Gracell Biotechnologies Inc. Is Fair to ShareholdersDecember 22, 2023 | marketbeat.comGracell Biotechnologies Inc. (NASDAQ:GRCL) Given Average Recommendation of "Buy" by BrokeragesGracell Biotechnologies Inc. (NASDAQ:GRCL - Get Free Report) has earned an average rating of "Buy" from the six analysts that are presently covering the company, MarketBeat.com reports. Six investment analysts have rated the stock with a buy rating. The average 12 month target price among analystsDecember 21, 2023 | finance.yahoo.comGracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus ErythematosusDecember 21, 2023 | finance.yahoo.comGracell Biotechnologies Inc. Sponsored ADR (GRCL) Is a Great Choice for 'Trend' Investors, Here's WhyDecember 18, 2023 | marketbeat.comPivotal bioVenture Partners Investment Advisor LLC Invests $3.96 Million in Gracell Biotechnologies Inc. (NASDAQ:GRCL)Pivotal bioVenture Partners Investment Advisor LLC purchased a new stake in Gracell Biotechnologies Inc. (NASDAQ:GRCL - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 1,375,000 shares oDecember 16, 2023 | marketbeat.comGracell Biotechnologies Inc. (NASDAQ:GRCL) Short Interest UpdateGracell Biotechnologies Inc. (NASDAQ:GRCL - Get Free Report) was the target of a large increase in short interest during the month of November. As of November 30th, there was short interest totalling 1,010,000 shares, an increase of 9.5% from the November 15th total of 922,400 shares. Based on an average trading volume of 493,100 shares, the short-interest ratio is currently 2.0 days. Approximately 1.4% of the company's shares are short sold.December 12, 2023 | finance.yahoo.comGracell Biotechnologies Presents Updated Clinical Data from FasTCAR-T GC012F Demonstrating Deep and Durable Responses in Newly Diagnosed Multiple Myeloma at ASH 2023December 11, 2023 | finance.yahoo.comWall Street Analysts Believe Gracell Biotechnologies Inc. Sponsored ADR (GRCL) Could Rally 127.82%: Here's is How to TradeDecember 2, 2023 | finance.yahoo.comInstitutions own 19% of Gracell Biotechnologies Inc. (NASDAQ:GRCL) shares but private equity firms control 45% of the companyNovember 29, 2023 | markets.businessinsider.comBuy Rating for Gracell Biotechnologies on Promising CAR-T Cell Therapy AdvancementsNovember 28, 2023 | msn.comEvercore ISI Group Initiates Coverage of Gracell Biotechnologies Inc - ADR (GRCL) with Outperform RecommendationNovember 27, 2023 | marketwatch.comGracell Biotechnologies Shares Rise 9%, FDA Clears Application for Lupus TreatmentNovember 27, 2023 | markets.businessinsider.comGracell Biotechnologies: FDA Clears IND Application For Phase 1/2 Trial Of FasTCAR-T GC012FNovember 27, 2023 | finance.yahoo.comGracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus ErythematosusNovember 23, 2023 | finance.yahoo.comWhat Makes Gracell Biotechnologies Inc. Sponsored ADR (GRCL) a Strong Momentum Stock: Buy Now?November 23, 2023 | finance.yahoo.comDoes Gracell Biotechnologies Inc. Sponsored ADR (GRCL) Have the Potential to Rally 120.94% as Wall Street Analysts Expect?November 16, 2023 | finanznachrichten.deGracell Biotechnologies Inc.: Gracell Biotechnologies to Participate in Inaugural Cell Therapy for Autoimmune Disease SummitNovember 16, 2023 | finance.yahoo.comGracell Biotechnologies to Participate in Inaugural Cell Therapy for Autoimmune Disease SummitNovember 14, 2023 | markets.businessinsider.comPositive Outlook for Gracell Biotechnologies: Promising Translational Data and Financial Stability Backs Buy RatingNovember 14, 2023 | markets.businessinsider.comGracell Biotechnologies: Promising Developments in Systemic Lupus Erythematosus Treatment Augment Buy Rating Get Gracell Biotechnologies News Delivered to You Automatically Sign up to receive the latest news and ratings for GRCL and its competitors with MarketBeat's FREE daily newsletter. Email Address What’s Really Next for America… (Ad)Millions of Unsuspecting Americans Could be Wiped Out… Yet those who watch this bombshell exposé and prepare before it’s too late could have the chance to protect their financial future and grow their wealth significantly. Click here to stream this controversial exposé now. GRCL Media Mentions By Week GRCL Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GRCL News Sentiment▼0.000.57▲Average Medical News Sentiment GRCL News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GRCL Articles This Week▼02▲GRCL Articles Average Week Get Gracell Biotechnologies News Delivered to You Automatically Sign up to receive the latest news and ratings for GRCL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: SIGA News ARCT News COGT News PRTC News YMAB News ATRI News AUPH News MD News IRON News SVRA News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GRCL) was last updated on 5/13/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsThe Crypto 9-5 Escape PlanCrypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market InsidersBuy this small stock before coming AI Tidal WaveChaikin AnalyticsElon’s New Device is About to Shock the WorldInvestorPlaceUrgent Nvidia WarningAltimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gracell Biotechnologies Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
